Ann Baker and John Cole are speaking on this topic. This webinar will examine the motivations for collaboration between biopharma and academia – two different worlds. Crucially, we will also reflect on why the outcomes of such collaborations often disappoint and consider some of the interventions that both parties can make to ensure a successful outcome. We will look at how to bridge the gap between academia and biopharma.
For more information on this event, click here.
CRA's RADAR Insights: Factors impacting GKV rebates for orphan drugs in Germany - Part 1
Germany’s AMNOG introduced in 2011 follows health technology assessments (HTAs) with reimbursement price negotiations and some exceptions for orphan drugs...